Bharat Biotech promoter Krishna Ella becomes new IVMA president

Bharat Biotech co-founder Krishna M Ella was appointed president of the Indian Vaccine Manufacturers Association (IVMA) for a two-year term from April 2024 to 2026. Krishna M Ella has taken over from Adar C Poonawala.

• Krishna M Ella aims to strengthen collaboration between vaccine manufacturers, researchers. Policymakers have been asked to accelerate vaccine development and improve production. The Indian Vaccine Manufacturers Association (IVMA) also wants to support developing countries' access to affordable vaccines.

Krishna M Ella replaces Adar Poonawala:

• Adar Poonawalla has served as the Chief Executive Officer of the Serum Institute of India (SII) since 2011.
• SII became the first Indian company to introduce AstraZeneca and Oxford vaccines under the brand name Covishield during Covid-19.
• Krishna M Ella takes over as chairman from Adar C Poonawalla, who held the post from 2019 to March 2024.

Appointment to other posts of IVMA:

• Along with the appointment of the President of Krishna M Ella, other important posts of IVMA were also announced. The following were included under this:
  • Mahima Datla, managing director of Biological E, has been  appointed vice-chairman.
  • T. Srinivas, chief financial officer (CFO) of Bharat Biotech, will be the treasurer.
  • Dr. Harsh Vardhan will continue as the Director General of IVMA.

About Indian Vaccine Manufacturers Association (IVMA):

• IVMA works to create and maintain an environment conducive to the development of vaccination using vaccines in India. This creates a partnership between industry, government and civil society.
• IVMA is a non-governmental apex body, not-for-profit, industry-led and industry-managed organization. It is playing an active role in the Indian health care development process.
• IVMA was established in 2010 by four founding members from the private sector. IVMA is the voice of India's vaccine business and industry.

Function of IVMA:

• IVMA charts working closely with the government on vaccine policy issues.
• Connecting with thought leaders.
• To work to enhance efficiency, competitiveness and business opportunities for the vaccine industry in India through a range of specialized services and strategic global relationships.
• IVMA also provides a platform for consensus building and networking on key issues.
• Expanding its agenda beyond business, IVMA helps industry identify and implement corporate citizenship programs.

About Vaccine:

• The medicine which is given in the form of drops, injection or any other form to develop immunity against any infectious disease is called a vaccine. Vaccines are considered an important pillar of global health.
• Vaccination is the most effective method for preventing infectious diseases.
• Vaccination works by increasing the immunity of a person and destroying the microorganisms produced in the body.
• Vaccination is one of the most cost-effective health investments.